Avrin Pharma Ltd 09866322 false 2023-12-01 2024-11-30 2024-11-30 The principal activity of the company is Pharmaceutical consultancy Digita Accounts Production Advanced 6.30.9574.0 true 09866322 2023-12-01 2024-11-30 09866322 2024-11-30 09866322 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 09866322 core:Non-currentFinancialInstruments core:AfterOneYear 2024-11-30 09866322 bus:Micro-entities 2023-12-01 2024-11-30 09866322 bus:AuditExemptWithAccountantsReport 2023-12-01 2024-11-30 09866322 bus:FullAccounts 2023-12-01 2024-11-30 09866322 bus:SmallCompaniesRegimeForAccounts 2023-12-01 2024-11-30 09866322 bus:RegisteredOffice 2023-12-01 2024-11-30 09866322 bus:Director1 2023-12-01 2024-11-30 09866322 bus:PrivateLimitedCompanyLtd 2023-12-01 2024-11-30 09866322 countries:England 2023-12-01 2024-11-30 09866322 dpl:AdministrativeExpenses 2023-12-01 2024-11-30 09866322 2022-12-01 2023-11-30 09866322 2023-11-30 09866322 core:CurrentFinancialInstruments core:WithinOneYear 2023-11-30 09866322 core:Non-currentFinancialInstruments core:AfterOneYear 2023-11-30 09866322 dpl:AdministrativeExpenses 2022-12-01 2023-11-30 iso4217:GBP xbrli:pure

Registration number: 09866322

Avrin Pharma Ltd

Annual Report and Unaudited Financial Statements

for the Year Ended 30 November 2024

 

Avrin Pharma Ltd

Contents

Company Information

1

Profit and Loss Account

3

Balance Sheet

4

Notes to the Unaudited Financial Statements

4

 

Avrin Pharma Ltd

Company Information

Director

Mr EK Naderali

Registered office

13 Walton Vale
Liverpool
Merseyside
L9 4RE

Accountants

JBRS Accountants Limited
13 Walton Vale
Liverpool
Merseyside
L9 4RE

 

Avrin Pharma Ltd

iXBRL Detailed Profit and Loss Account for the Year Ended 30 November 2024

2024
 £

2023
 £

Turnover/revenue

25,714

7,973

Cost of sales

Distribution costs

Administrative expenses

Audit and accountancy other services

(972)

(1,092)

Client entertaining costs

(584)

(71)

Other repairs and maintenance costs

-

(50)

Depreciation of property, plant and equipment

(520)

(468)

Vehicle costs

(6,032)

-

Travel and subsistence

(5,129)

(2,732)

Legal and professional costs

(55)

(13)

Bank charges

(90)

(82)

Insurance costs

(362)

(230)

Telecommunications

(1,120)

(488)

Printing, postage and stationery

(238)

(102)

Subscriptions

-

(700)

Other costs

(360)

(360)

Other operating income

Other items

Profit on ordinary activities before finance charges and interest

10,252

1,585

Non-bank interest and similar charges

-

(2)

Profit for the financial year

10,252

1,583

 

Avrin Pharma Ltd

Profit and Loss Account for the Year Ended 30 November 2024

2024
£

2023
£

Turnover

25,714

7,973

Depreciation and other amounts written off assets

(520)

(468)

Other charges

(14,942)

(5,922)

Profit for the year

10,252

1,583

 

Avrin Pharma Ltd

(Registration number: 09866322)
Balance Sheet as at 30 November 2024

2024
£

2023
£

Fixed assets

16,046

16,237

Current assets

9,264

6,211

Creditors: Amounts falling due within one year

(1,887)

(1,379)

Net current assets

7,377

4,832

Total assets less current liabilities

23,423

21,069

Creditors: Amounts falling due after more than one year

(8,904)

(16,835)

Accruals and deferred income

(1,042)

(1,009)

 

13,477

3,225

Capital and reserves

13,477

3,225

1

General information

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2023 - 1).

For the financial year ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Approved and authorised by the director on 21 February 2025
 

.........................................
Mr EK Naderali
Director